Skip to main content
Top
Published in: Neurocritical Care 3/2015

01-12-2015 | Original Article

Cohort-Based Identification of Predictors of Symptomatic Intracerebral Hemorrhage After IV Thrombolysis

Authors: David Asuzu, Karin Nyström, Hardik Amin, Joseph Schindler, Charles Wira, David Greer, Nai Fang Chi, Janet Halliday, Kevin N. Sheth

Published in: Neurocritical Care | Issue 3/2015

Login to get access

Abstract

Introduction

Symptomatic intracranial hemorrhage (sICH) is a serious complication of IV rt-PA therapy after acute ischemic stroke. Independent sICH predictors have been previously derived using case–control studies. Here we utilized a novel cohort-based comparison to identify additional independent predictors of sICH.

Methods

We included 210 patients receiving IV rt-PA therapy from January 2009 through December 2013 at the Yale-New Haven Stroke Center. Clinical parameters were compared using Mann–Whitney tests, two-sample tests of proportions and two-sample t tests. Logistic regression was performed using sICH as the dependent variable. Predictive ability was assessed using areas under the receiver operating characteristic (ROC) curve.

Results

sICH rates were lowest from 2010 to 2012 and comprised the low sICH cohort (2.0 % sICH), compared to the high sICH cohort from 2009 to 2013 (9.2 % sICH, P = 0.025). Patients in the low sICH cohort had significantly more visual field deficits (38.6 vs. 24.8 %, P = 0.03) and decreased levels of consciousness (62.4 vs. 39.4 %, P < 0.001), but fewer hyperdense MCA signs (5 vs. 13.8 %, P = 0.03) and early CT hypodensities (14.9 vs. 29.4 %, P = 0.01). These four parameters together predicted sICH modestly (area under ROC curve 0.66, odds ratio 2.72, P = 0.03)

Conclusions

Using a novel cohort-based approach, we identified two new independent predictors of sICH after IV rt-PA therapy: the presence of the hyperdense MCA sign and early CT hypodensities. Novel methods are needed to reduce the risk of sICH for patients receiving antithrombolytic therapy for ischemic stroke.
Literature
1.
go back to reference Go AS, Mozaffarian D, Roger VL, et al. Heart disease and stroke statistics–2013 update: a report from the American Heart Association. Circulation. 2013;127(1):e6–245.CrossRefPubMed Go AS, Mozaffarian D, Roger VL, et al. Heart disease and stroke statistics–2013 update: a report from the American Heart Association. Circulation. 2013;127(1):e6–245.CrossRefPubMed
2.
go back to reference The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995;333(24):1581–7.CrossRef The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995;333(24):1581–7.CrossRef
3.
go back to reference Larrue V, von Kummer RR, Muller A, Bluhmki E. Risk factors for severe hemorrhagic transformation in ischemic stroke patients treated with recombinant tissue plasminogen activator: a secondary analysis of the European-Australasian Acute Stroke Study (ECASS II). Stroke. 2001;32(2):438–41.CrossRefPubMed Larrue V, von Kummer RR, Muller A, Bluhmki E. Risk factors for severe hemorrhagic transformation in ischemic stroke patients treated with recombinant tissue plasminogen activator: a secondary analysis of the European-Australasian Acute Stroke Study (ECASS II). Stroke. 2001;32(2):438–41.CrossRefPubMed
4.
go back to reference Kwiatkowski TG, Libman RB, Frankel M, et al. Effects of tissue plasminogen activator for acute ischemic stroke at one year. National Institute of Neurological Disorders and Stroke Recombinant Tissue Plasminogen Activator Stroke Study Group. N Engl J Med. 1999;340(23):1781–7.CrossRefPubMed Kwiatkowski TG, Libman RB, Frankel M, et al. Effects of tissue plasminogen activator for acute ischemic stroke at one year. National Institute of Neurological Disorders and Stroke Recombinant Tissue Plasminogen Activator Stroke Study Group. N Engl J Med. 1999;340(23):1781–7.CrossRefPubMed
5.
go back to reference Schmulling S, Grond M, Rudolf J, Heiss WD. One-year follow-up in acute stroke patients treated with rtPA in clinical routine. Stroke. 2000;31(7):1552–4.CrossRefPubMed Schmulling S, Grond M, Rudolf J, Heiss WD. One-year follow-up in acute stroke patients treated with rtPA in clinical routine. Stroke. 2000;31(7):1552–4.CrossRefPubMed
6.
go back to reference Hong KS, Yegiaian S, Lee M, Lee J, Saver JL. Declining stroke and vascular event recurrence rates in secondary prevention trials over the past 50 years and consequences for current trial design. Circulation. 2011;123(19):2111–9.PubMedCentralCrossRefPubMed Hong KS, Yegiaian S, Lee M, Lee J, Saver JL. Declining stroke and vascular event recurrence rates in secondary prevention trials over the past 50 years and consequences for current trial design. Circulation. 2011;123(19):2111–9.PubMedCentralCrossRefPubMed
7.
go back to reference Brown DL, Barsan WG, Lisabeth LD, Gallery ME, Morgenstern LB. Survey of emergency physicians about recombinant tissue plasminogen activator for acute ischemic stroke. Ann Emerg Med. 2005;46(1):56–60.CrossRefPubMed Brown DL, Barsan WG, Lisabeth LD, Gallery ME, Morgenstern LB. Survey of emergency physicians about recombinant tissue plasminogen activator for acute ischemic stroke. Ann Emerg Med. 2005;46(1):56–60.CrossRefPubMed
8.
go back to reference Miettinen O. Estimability and estimation in case-referent studies. Am J Epidemiol. 1976;103(2):226–35.PubMed Miettinen O. Estimability and estimation in case-referent studies. Am J Epidemiol. 1976;103(2):226–35.PubMed
9.
go back to reference Rodrigues L, Kirkwood BR. Case-control designs in the study of common diseases: updates on the demise of the rare disease assumption and the choice of sampling scheme for controls. Int J Epidemiol. 1990;19(1):205–13.CrossRefPubMed Rodrigues L, Kirkwood BR. Case-control designs in the study of common diseases: updates on the demise of the rare disease assumption and the choice of sampling scheme for controls. Int J Epidemiol. 1990;19(1):205–13.CrossRefPubMed
10.
11.
go back to reference Asuzu D, Nystrom K, Amin H, et al. Comparison of 8 scores for predicting symptomatic intracerebral hemorrhage after IV thrombolysis. Neurocrit Care. 2014. doi:10.1007/s12028-014-0060-2. Asuzu D, Nystrom K, Amin H, et al. Comparison of 8 scores for predicting symptomatic intracerebral hemorrhage after IV thrombolysis. Neurocrit Care. 2014. doi:10.​1007/​s12028-014-0060-2.
12.
go back to reference Jauch EC, Saver JL, Adams HP Jr, et al. Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2013;44(3):870–947.CrossRefPubMed Jauch EC, Saver JL, Adams HP Jr, et al. Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2013;44(3):870–947.CrossRefPubMed
13.
go back to reference DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics. 1988;44(3):837–45.CrossRefPubMed DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics. 1988;44(3):837–45.CrossRefPubMed
14.
go back to reference Alvarez-Sabin J, Maisterra O, Santamarina E, Kase CS. Factors influencing haemorrhagic transformation in ischaemic stroke. Lancet Neurol. 2013;12(7):689–705.CrossRefPubMed Alvarez-Sabin J, Maisterra O, Santamarina E, Kase CS. Factors influencing haemorrhagic transformation in ischaemic stroke. Lancet Neurol. 2013;12(7):689–705.CrossRefPubMed
15.
go back to reference Weiser RE, Sheth KN. Clinical predictors and management of hemorrhagic transformation. Curr Treat Options neurol. 2013;15(2):125–49.CrossRefPubMed Weiser RE, Sheth KN. Clinical predictors and management of hemorrhagic transformation. Curr Treat Options neurol. 2013;15(2):125–49.CrossRefPubMed
16.
go back to reference Ingall TJ, O’Fallon WM, Asplund K, et al. Findings from the reanalysis of the NINDS tissue plasminogen activator for acute ischemic stroke treatment trial. Stroke. 2004;35(10):2418–24.CrossRefPubMed Ingall TJ, O’Fallon WM, Asplund K, et al. Findings from the reanalysis of the NINDS tissue plasminogen activator for acute ischemic stroke treatment trial. Stroke. 2004;35(10):2418–24.CrossRefPubMed
17.
go back to reference Kent TA. Predicting outcome of IV thrombolysis-treated ischemic stroke patients: the DRAGON score. Neurology. 2012;78(17):1368.CrossRefPubMed Kent TA. Predicting outcome of IV thrombolysis-treated ischemic stroke patients: the DRAGON score. Neurology. 2012;78(17):1368.CrossRefPubMed
18.
go back to reference Saposnik G, Raptis S, Kapral MK, et al. The iScore predicts poor functional outcomes early after hospitalization for an acute ischemic stroke. Stroke. 2011;42(12):3421–8.CrossRefPubMed Saposnik G, Raptis S, Kapral MK, et al. The iScore predicts poor functional outcomes early after hospitalization for an acute ischemic stroke. Stroke. 2011;42(12):3421–8.CrossRefPubMed
19.
go back to reference Strbian D, Meretoja A, Ahlhelm FJ, et al. Predicting outcome of IV thrombolysis-treated ischemic stroke patients: the DRAGON score. Neurology. 2012;78(6):427–32.CrossRefPubMed Strbian D, Meretoja A, Ahlhelm FJ, et al. Predicting outcome of IV thrombolysis-treated ischemic stroke patients: the DRAGON score. Neurology. 2012;78(6):427–32.CrossRefPubMed
20.
go back to reference Saposnik G, Guzik AK, Reeves M, Ovbiagele B, Johnston SC. Stroke prognostication using age and NIH stroke scale: SPAN-100. Neurology. 2013;80(1):21–8.PubMedCentralCrossRefPubMed Saposnik G, Guzik AK, Reeves M, Ovbiagele B, Johnston SC. Stroke prognostication using age and NIH stroke scale: SPAN-100. Neurology. 2013;80(1):21–8.PubMedCentralCrossRefPubMed
21.
go back to reference Ntaios G, Faouzi M, Ferrari J, Lang W, Vemmos K, Michel P. An integer-based score to predict functional outcome in acute ischemic stroke: the ASTRAL score. Neurology. 2012;78(24):1916–22.CrossRefPubMed Ntaios G, Faouzi M, Ferrari J, Lang W, Vemmos K, Michel P. An integer-based score to predict functional outcome in acute ischemic stroke: the ASTRAL score. Neurology. 2012;78(24):1916–22.CrossRefPubMed
22.
go back to reference Cucchiara B, Tanne D, Levine SR, Demchuk AM, Kasner S. A risk score to predict intracranial hemorrhage after recombinant tissue plasminogen activator for acute ischemic stroke. J Stroke Cerebrovasc Dis. 2008;17(6):331–3.CrossRefPubMed Cucchiara B, Tanne D, Levine SR, Demchuk AM, Kasner S. A risk score to predict intracranial hemorrhage after recombinant tissue plasminogen activator for acute ischemic stroke. J Stroke Cerebrovasc Dis. 2008;17(6):331–3.CrossRefPubMed
23.
go back to reference Lou M, Safdar A, Mehdiratta M, et al. The HAT score: a simple grading scale for predicting hemorrhage after thrombolysis. Neurology. 2008;71(18):1417–23.PubMedCentralCrossRefPubMed Lou M, Safdar A, Mehdiratta M, et al. The HAT score: a simple grading scale for predicting hemorrhage after thrombolysis. Neurology. 2008;71(18):1417–23.PubMedCentralCrossRefPubMed
24.
go back to reference Strbian D, Engelter S, Michel P, et al. Symptomatic intracranial hemorrhage after stroke thrombolysis: the SEDAN score. Annals Neurol. 2012;71(5):634–41.CrossRef Strbian D, Engelter S, Michel P, et al. Symptomatic intracranial hemorrhage after stroke thrombolysis: the SEDAN score. Annals Neurol. 2012;71(5):634–41.CrossRef
25.
go back to reference Mazya M, Egido JA, Ford GA, et al. Predicting the risk of symptomatic intracerebral hemorrhage in ischemic stroke treated with intravenous alteplase: safe implementation of treatments in stroke (SITS) symptomatic intracerebral hemorrhage risk score. Stroke. 2012;43(6):1524–31.CrossRefPubMed Mazya M, Egido JA, Ford GA, et al. Predicting the risk of symptomatic intracerebral hemorrhage in ischemic stroke treated with intravenous alteplase: safe implementation of treatments in stroke (SITS) symptomatic intracerebral hemorrhage risk score. Stroke. 2012;43(6):1524–31.CrossRefPubMed
26.
go back to reference Kent DM, Selker HP, Ruthazer R, Bluhmki E, Hacke W. The stroke-thrombolytic predictive instrument: a predictive instrument for intravenous thrombolysis in acute ischemic stroke. Stroke. 2006;37(12):2957–62.CrossRefPubMed Kent DM, Selker HP, Ruthazer R, Bluhmki E, Hacke W. The stroke-thrombolytic predictive instrument: a predictive instrument for intravenous thrombolysis in acute ischemic stroke. Stroke. 2006;37(12):2957–62.CrossRefPubMed
27.
go back to reference Sung SF, Chen CH, Chen YW, Tseng MC, Shen HC, Lin HJ. Predicting symptomatic intracerebral hemorrhage after intravenous thrombolysis: stroke territory as a potential pitfall. J Neurol Sci. 2013;335(1–2):96–100.CrossRefPubMed Sung SF, Chen CH, Chen YW, Tseng MC, Shen HC, Lin HJ. Predicting symptomatic intracerebral hemorrhage after intravenous thrombolysis: stroke territory as a potential pitfall. J Neurol Sci. 2013;335(1–2):96–100.CrossRefPubMed
28.
go back to reference Chen C, Ye M, Chen BL, et al. Thrombolysis on ischemic stroke patients with decreased level of consciousness within 4.5 h. CNS Neurosci Ther. 2013;19(1):48–52.CrossRefPubMed Chen C, Ye M, Chen BL, et al. Thrombolysis on ischemic stroke patients with decreased level of consciousness within 4.5 h. CNS Neurosci Ther. 2013;19(1):48–52.CrossRefPubMed
29.
go back to reference Kharitonova T, Ahmed N, Thoren M, et al. Hyperdense middle cerebral artery sign on admission CT scan–prognostic significance for ischaemic stroke patients treated with intravenous thrombolysis in the safe implementation of thrombolysis in Stroke International Stroke Thrombolysis Register. Cerebrovasc Dis. 2009;27(1):51–9.CrossRefPubMed Kharitonova T, Ahmed N, Thoren M, et al. Hyperdense middle cerebral artery sign on admission CT scan–prognostic significance for ischaemic stroke patients treated with intravenous thrombolysis in the safe implementation of thrombolysis in Stroke International Stroke Thrombolysis Register. Cerebrovasc Dis. 2009;27(1):51–9.CrossRefPubMed
30.
go back to reference Pexman JH, Barber PA, Hill MD, et al. Use of the Alberta Stroke Program Early CT Score (ASPECTS) for assessing CT scans in patients with acute stroke. AJNR Am J Neuroradiol. 2001;22(8):1534–42.PubMed Pexman JH, Barber PA, Hill MD, et al. Use of the Alberta Stroke Program Early CT Score (ASPECTS) for assessing CT scans in patients with acute stroke. AJNR Am J Neuroradiol. 2001;22(8):1534–42.PubMed
31.
go back to reference Demchuk AM, Hill MD, Barber PA, et al. Importance of early ischemic computed tomography changes using ASPECTS in NINDS rtPA stroke study. Stroke. 2005;36(10):2110–5.CrossRefPubMed Demchuk AM, Hill MD, Barber PA, et al. Importance of early ischemic computed tomography changes using ASPECTS in NINDS rtPA stroke study. Stroke. 2005;36(10):2110–5.CrossRefPubMed
32.
go back to reference Dzialowski I, Hill MD, Coutts SB, et al. Extent of early ischemic changes on computed tomography (CT) before thrombolysis: prognostic value of the Alberta Stroke Program Early CT Score in ECASS II. Stroke. 2006;37(4):973–8.CrossRefPubMed Dzialowski I, Hill MD, Coutts SB, et al. Extent of early ischemic changes on computed tomography (CT) before thrombolysis: prognostic value of the Alberta Stroke Program Early CT Score in ECASS II. Stroke. 2006;37(4):973–8.CrossRefPubMed
33.
go back to reference Lyden P. Early major ischemic changes on computed tomography should not preclude use of tissue plasminogen activator. Stroke. 2003;34(3):821–2.CrossRefPubMed Lyden P. Early major ischemic changes on computed tomography should not preclude use of tissue plasminogen activator. Stroke. 2003;34(3):821–2.CrossRefPubMed
34.
go back to reference von Kummer R. Early major ischemic changes on computed tomography should preclude use of tissue plasminogen activator. Stroke. 2003;34(3):820–1.CrossRef von Kummer R. Early major ischemic changes on computed tomography should preclude use of tissue plasminogen activator. Stroke. 2003;34(3):820–1.CrossRef
35.
go back to reference Gumbinger C, Gruschka P, Bottinger M, et al. Improved prediction of poor outcome after thrombolysis using conservative definitions of symptomatic hemorrhage. Stroke. 2012;43(1):240–2.CrossRefPubMed Gumbinger C, Gruschka P, Bottinger M, et al. Improved prediction of poor outcome after thrombolysis using conservative definitions of symptomatic hemorrhage. Stroke. 2012;43(1):240–2.CrossRefPubMed
36.
go back to reference Hacke W, Kaste M, Fieschi C, et al. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators. Lancet. 1998;352(9136):1245–51.CrossRefPubMed Hacke W, Kaste M, Fieschi C, et al. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators. Lancet. 1998;352(9136):1245–51.CrossRefPubMed
37.
go back to reference Wahlgren N, Ahmed N, Davalos A, et al. Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study. Lancet. 2007;369(9558):275–82.CrossRefPubMed Wahlgren N, Ahmed N, Davalos A, et al. Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study. Lancet. 2007;369(9558):275–82.CrossRefPubMed
38.
go back to reference Strbian D, Michel P, Seiffge DJ, et al. Symptomatic intracranial hemorrhage after stroke thrombolysis: comparison of prediction scores. Stroke. 2014;45(3):752–8.CrossRefPubMed Strbian D, Michel P, Seiffge DJ, et al. Symptomatic intracranial hemorrhage after stroke thrombolysis: comparison of prediction scores. Stroke. 2014;45(3):752–8.CrossRefPubMed
39.
go back to reference Sung SF, Chen SC, Lin HJ, Chen YW, Tseng MC, Chen CH. Comparison of risk-scoring systems in predicting symptomatic intracerebral hemorrhage after intravenous thrombolysis. Stroke. 2013;44(6):1561–6.CrossRefPubMed Sung SF, Chen SC, Lin HJ, Chen YW, Tseng MC, Chen CH. Comparison of risk-scoring systems in predicting symptomatic intracerebral hemorrhage after intravenous thrombolysis. Stroke. 2013;44(6):1561–6.CrossRefPubMed
Metadata
Title
Cohort-Based Identification of Predictors of Symptomatic Intracerebral Hemorrhage After IV Thrombolysis
Authors
David Asuzu
Karin Nyström
Hardik Amin
Joseph Schindler
Charles Wira
David Greer
Nai Fang Chi
Janet Halliday
Kevin N. Sheth
Publication date
01-12-2015
Publisher
Springer US
Published in
Neurocritical Care / Issue 3/2015
Print ISSN: 1541-6933
Electronic ISSN: 1556-0961
DOI
https://doi.org/10.1007/s12028-015-0121-1

Other articles of this Issue 3/2015

Neurocritical Care 3/2015 Go to the issue